Summary:
A Phase 2, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study, with a 28-week active treatment extension, to evaluate the efficacy and safety of CC-90001 in subjects with idiopathic pulmonary fibrosis.
Qualified Participants Must:
• Must be taking Esbriet for at least 8 weeks prior to screening visit.
Qualified Participants May Receive:
Free medical services, to include but not limited to: HRCT, EKG, monthly lab evaluations, doctor visits with physical and monitoring of disease (no insurance billed). Subjects will also receive $100 per visit as well as compensation for travel/lodging expenses.